Skip to content

AbbVie ABBV Income Statement

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
$62.82B+9.5%$61.16B+8.6%$59.64B+7.4%$58.33B+6.1%$57.37B+5.4%
$18.42B+9.6%$18.2B+7.7%$18.05B-0.9%$16.96B-17.2%$16.81B-18.1%
$44.4B+9.5%$42.96B+8.9%$41.6B+11.5%$41.37B+19.9%$40.56B+19.7%
70.7%0.0pp70.2%+0.2pp69.7%+2.5pp70.9%+8.2pp70.7%+8.4pp
$14.3B-3.0%$14.01B-5.0%$13.97B-0.9%$14.61B+10.2%$14.73B+12.0%
$47.49B+0.4%$46.09B-2.4%$50.6B+21.3%$47.36B+10.8%$47.3B+13.6%
$15.33B$15.08B
24.4%24.6%
$5.98B$6.6B
$2.33B+502%$2.36B+515%-$735M-136%-$741M-143%-$581M-138%
$3.64B-13.3%$4.23B-1.2%$2.39B-53.4%$3.76B-29.5%$4.2B-30.0%
5.8%-1.5pp6.9%-0.7pp4%-5.2pp6.5%-3.3pp7.3%-3.7pp
$2.03-13.6%$2.36-1.7%$1.32-54.2%$2.10-30.0%$2.35-30.3%
$2.03-13.6%$2.36-1.7%$1.32-54.2%$2.10-30.0%$2.35-30.3%
7.1B0.0%7.1B0.0%7.1B0.0%7.1B0.0%7.1B0.0%
7.1B0.0%7.1B0.0%7.1B0.0%7.1B0.0%7.1B0.0%
$5.51B+94.0%$5.02B+81.9%$5.33B+263%$2.73B+88.2%$2.84B+259%
-$2.65B-13.3%-$2.63B-21.6%-$2.58B-33.9%-$2.51B-44.4%-$2.33B-38.7%
-$2.65B-13.3%-$2.63B-21.6%-$2.58B-33.9%-$2.51B-44.4%-$2.33B-38.7%
-$2.65B-13.3%-$2.63B-21.6%-$2.58B-33.9%-$2.51B-44.4%-$2.33B-38.7%
-$6.66B-62.4%-$5.8B-78.9%-$4.74B-2.0%-$5.39B-59.0%-$4.1B-18.5%
$9.5B-26.5%$9.1B-28.9%$13.29B+67.3%$13.1B+73.8%$12.92B+76.4%
$15.33B$15.08B
$23.43B$23.28B
$23.43B$23.28B
37.3%38.1%
$15.33B$15.08B

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What is AbbVie's revenue?
AbbVie (ABBV) generated $62.8B in revenue over the trailing twelve months, up 9.5% year over year.
Is AbbVie profitable?
AbbVie reported $3.6B in net income over the trailing twelve months, a 5.8% net margin.
What are AbbVie's profit margins?
Gross margin is 70.7% and operating margin is 24.4%, with a 5.8% net margin.
What is AbbVie's earnings per share?
AbbVie's diluted EPS over the trailing twelve months is $2.03.
Where does AbbVie's income statement data come from?
Every line is extracted from AbbVie's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.